U.S. Markets closed
  • Gold

    1,807.40
    +0.60 (+0.03%)
     
  • EUR/USD

    1.1606
    -0.0008 (-0.0696%)
     
  • 10-Yr Bond

    1.6350
    -0.0200 (-1.21%)
     
  • Vix

    15.24
    -0.19 (-1.23%)
     
  • GBP/USD

    1.3760
    -0.0009 (-0.0647%)
     
  • USD/JPY

    113.8330
    +0.1340 (+0.1179%)
     
  • BTC-USD

    63,053.09
    +1,341.67 (+2.17%)
     
  • CMC Crypto 200

    1,512.58
    +1,269.90 (+523.28%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Nikkei 225

    29,069.72
    +469.31 (+1.64%)
     

RNA Tech Vaccine Developer GreenLight Biosciences Riding To NASDAQ Debut Via $1.5B SPAC Deal

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • GreenLight Biosciences Inc is combining with a special-purpose acquisition company to go public in a deal that values the RNA-technology firm at about $1.5 billion.

  • GreenLight is merging with Environmental Impact Acquisition Corp (NASDAQ: ENVI), which is backed by investment bank Canaccord Genuity Group Inc.

  • GreenLight's ribonucleic acid (RNA) platform has developed candidates for COVID-19, influenza, and earlier-stage programs in sickle cell disease. It is simultaneously working on RNA-based sustainable alternatives to pesticides and herbicides.

  • The first biopesticide is slated to launch in 2022, the company said at the time of its series D.

  • The transaction will provide estimated proceeds of $282 million, including $105 million in proceeds from the PIPE transaction priced at $10.00 per share.

  • Price Action: ENVI shares are up 1.13% at $9.81 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.